<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127473</url>
  </required_header>
  <id_info>
    <org_study_id>NN7769-4882</org_study_id>
    <secondary_id>U1111-1266-4001</secondary_id>
    <secondary_id>2021-003182-35</secondary_id>
    <nct_id>NCT05127473</nct_id>
  </id_info>
  <brief_title>A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of Reformulated NNC0365-3769 (Mim8) in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NN0365-3769 (Mim8) is a study medicine with the potential to prevent and reduce bleeding in&#xD;
      people with haemophilia A (an inherited disorder in which blood does not coagulate properly).&#xD;
&#xD;
      This study will investigate if different doses of Mim8 are safe, and also check how Mim8&#xD;
      behaves in the body.&#xD;
&#xD;
      Twelve different doses will be tested. Participants will only get one of the doses. Which&#xD;
      dose participants get is decided by chance. Participants will get a single injection under&#xD;
      the skin of the belly by means of a syringe and a needle.&#xD;
&#xD;
      The study will last for about 17 - 21 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">April 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>Count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of injection site reactions</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, SD: the maximum concentration of Mim8 after a single dose</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>messured in μg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>messured in μg*day/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2, SD: the terminal half-life of Mim8 after a single dose</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>messured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, SD: the time to maximum concentration of Mim8 after a single dose</measure>
    <time_frame>From time of dosing (day 1) to day 113</time_frame>
    <description>messured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activated partial thromboplastin time</measure>
    <time_frame>From baseline (day 1) to day 113</time_frame>
    <description>messured in seconds</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteers - Haemophilia A</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive a single dose of Mim8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mim8 B, 10 mg/mL</intervention_name>
    <description>All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <other_name>NN0365-3769</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mim8 B, 100 mg/mL</intervention_name>
    <description>All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.</description>
    <arm_group_label>Dose level 10</arm_group_label>
    <arm_group_label>Dose level 11</arm_group_label>
    <arm_group_label>Dose level 12</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_label>Dose level 9</arm_group_label>
    <other_name>NN0365-3769</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mim8 B, placebo</intervention_name>
    <description>Placebo will be used to dilute the IMP to different Mim8 concentrations</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 11</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_label>Dose level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, aged 18-55 years (both inclusive) at the time of signing informed consent&#xD;
&#xD;
          -  Body mass index between 18.5 and 29.9 kg/m^2 (both inclusive)&#xD;
&#xD;
          -  Body weight between 60.0 to 100.0 kg (both inclusive)&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Increased risk of thrombosis, e.g. known history of personal or first-degree&#xD;
             relative(s) with unprovoked deep vein thrombosis&#xD;
&#xD;
          -  Any clinical signs or established diagnosis of venous or arterial thromboembolic&#xD;
             disease&#xD;
&#xD;
          -  Factor VIII activity greater than or equal to150% at screening&#xD;
&#xD;
          -  Any of the thrombophilia markers listed below:&#xD;
&#xD;
               -  Protein C, protein S or antithrombin below the lower normal laboratory range&#xD;
&#xD;
               -  Factor II activity, activated protein C resistance, lupus anticoagulant,&#xD;
                  anti-cardiolipin antibody (IgG and IgM) or anti-β2 glycoprotein I antibody (IgG&#xD;
                  and IgM) outside the normal laboratory range at screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

